Last reviewed · How we verify
Oral PF-07081532 and IV [14C]PF-07081532 — Competitive Intelligence Brief
phase 1
Live · refreshed every 30 min
Target snapshot
Oral PF-07081532 and IV [14C]PF-07081532 (oral-pf-07081532-and-iv-14c-pf-07081532) — Pfizer Inc..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Oral PF-07081532 and IV [14C]PF-07081532 TARGET | oral-pf-07081532-and-iv-14c-pf-07081532 | Pfizer Inc. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Oral PF-07081532 and IV [14C]PF-07081532 CI watch — RSS
- Oral PF-07081532 and IV [14C]PF-07081532 CI watch — Atom
- Oral PF-07081532 and IV [14C]PF-07081532 CI watch — JSON
- Oral PF-07081532 and IV [14C]PF-07081532 alone — RSS
Cite this brief
Drug Landscape (2026). Oral PF-07081532 and IV [14C]PF-07081532 — Competitive Intelligence Brief. https://druglandscape.com/ci/oral-pf-07081532-and-iv-14c-pf-07081532. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab